Clinical and echocardiographic findings of the study population
| Variable | Data |
|---|---|
| Clinical findings | |
| Age (years) | 68 ± 10 |
| Male sex | 341 (64%) |
| BMI (kg/m2) | 26.8 ± 4.3 |
| BMI ≥ 30 | 104 (20%) |
| Diabetes mellitus | 142 (27%) |
| Arterial hypertension | 344 (65%) |
| Hypercholesterolemia | 324 (61%) |
| Current smoker | 112 (21%) |
| Left bundle branch block | 26 (5%) |
| Permanent atrial fibrillation | 21 (4%) |
| Paced rhythm | 15 (3%) |
| Prior myocardial infarction | 98 (18%) |
| Prior CABG | 15 (3%) |
| Prior PCI | 125 (24%) |
| Known CAD | 150 (28%) |
| Ongoing medical therapy | |
| Angiotensin-converting-enzyme inhibitors | 151 (28%) |
| Angiotensin receptor blocker | 105 (20%) |
| Calcium-antagonist | 123 (23%) |
| β-Blocker | 189 (36%) |
| Statin | 309 (58%) |
| Antiplatelet | 229 (43%) |
| Anticoagulant | 31 (6%) |
| Echocardiographic findings | |
| Heart rate (beats/min) | 68 ± 11 |
| SBP (mmHg) | 134 ± 16 |
| DBP (mmHg) | 79 ± 9 |
| LVEDV (mL) | 88 ± 28 |
| LVESV (mL) | 37 ± 19 |
| SBP/LVESV | 4.4 ± 1.8 |
| LVEF | 59 ± 9 |
| LVEF < 50% | 58 (11%) |
| B-lines | 1.4 ± 3.8 |
| B-lines ≥ 2 | 108 (20%) |
| GLS (%) | 16.3 ± 3.2 |
| GLS ≤ 16.2% | 223 (42%) |
The data presented are mean ± SD or number (%) of patients. BMI: body mass index; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; CAD: coronary artery disease; SBP: systolic blood pressure; DBP: diastolic blood pressure; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; LVEF: left ventricular ejection fraction